Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 265-273 , June 2008

Endocrine effects of vasopressin in critically ill patients

  • Tarek Sharshar, MD, PhD (Attending Physician at the GICU)
    • ,
  • Djillali Annane, MD, PhD (Director of the General ICU)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +331 47 10 77 86; Fax: +331 47 10 77 83.

References 

  1. Antunes-Rodrigues J, de Castro M, Elias LLK, et al. Neuroendocrine control of body fluid metabolism. Physiological Reviews. 2003;84:169–208
  2. Nielsen S, Chou CL, Marples D, et al. A. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:1013–1017
  3. Klussmann E, Maric K, Rosenthal W. The mechanisms of aquaporin control in the renal collecting duct. Reviews of Physiology, Biochemistry and Pharmacology. 2000;141:33–95
  4. Tahara A, Tomura Y, Wada KI, et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics. 1997;282:301–308
  5. Burnier M, Fricker AF, Hayoz D, et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. European Journal of Clinical Pharmacology. 1999;55:633–637
  6. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  7. Annane D, Decaux G, Smith N, for the Conivaptan Study Group. Efficacy and safety of oral Conivaptan, a vasopressin-receptor antagonist, avaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. The American Journal of the Medical Sciences, in press.
  8. Chen JM, Cillinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation. 1999;100:II244–II246
  9. Kinoshita Y, Yahata K, Yoshiota T, et al. Long term renal preservation after brain death maintained with vasopressin and epinephrine. Transplant International. 1990;3:15–18
  10. Patel BM, Chittock DR, Russel JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–582
  11. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313–2319
  12. Albanes J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine. 2005;33:1897–1902
  13. Versteilen AM, Heemskerk AE, Groenveld AB, et al. Mechanisms of the urinary concentration defect and effect of desmopressin during endotoxemia in rats. Shock. 2007 Jul 26;Publish Ahead of Print [Epub ahead of print]
  14. Mc Cann SM. The ACTH-releasing activity of extracts of the posterior lobe of the pituitary (in vivo). Endocrinology. 1957;137:580–586
  15. Conte-Devoix B, Oliver C, Giraud P, et al. Adrenocorticotropin, and corticosterone secretion in Brattleboro rats. Endocrinology. 1982;110:2097–2100
  16. Holmes MC, Antoni FA, Aguilera G, Catt KJ. Magnocellular axons in passage through the median eminence release vasopressin. Nature. 1986;319:326–329
  17. Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Frontiers in Neuroendocrinology. 2004;25:132–149
  18. Tanoue A, Ito S, Honda K, et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary adrenal axis activity under both stress and resting conditions. The Journal of Clinical Investigation. 2004;113:302–309
  19. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Frontiers in Neuroendocrinology. 1993;14:76–122
  20. Turnball AV, Smith GW, Lee S, et al. CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology. 1999;140:1013–1017
  21. Wotjak CT, Ludwig M, Ebner K, et al. Vasopressin from hypothalamic magnocellular neurons has opposite actions at the adenohypophysis and in the supraoptic nucleus on ACTH secretion. The European Journal of Neuroscience. 2002;16:477–485
  22. Perraudin V, Delarue C, Lefebvre H, et al. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. The Journal of Clinical Endocrinology and Metabolism. 1993;76:1522–1528
  23. Guillon G, Trueba M, Joubert D, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 1995;136:1285–1295
  24. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Critical Care Medicine. 2003;31:1752–1758
  25. Oahwash IM, Cassar CA, Radcliff RP, Smith GW. Bacterial lipopolysaccharide-induced coordinate downregulation of arginine vasopressine receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers. Endocrine. 2002;18:13–20
  26. Kornberger E, Prengel AW, Krismer A, et al. Vasopressin-mediated adrenocorticotropin release increases plasma cortisol concentrations during cardiopulmonary resuscitation. Critical Care Medicine. 2000;28:3517–3521
  27. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine. 2006;32:1782–1789
  28. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Critical Care Medicine. 2001;29:487–493
  29. Itoh H, Nakao K, Yamada T, et al. Modulatory role of vasopressin in secretion of atrial natriuretic polypeptide in conscious rats. Endocrinology. 1987;120:2186–2188
  30. Cogan E, Debieve MF, Philipart I, et al. High plasma levels of atrial natriuretic factor in SIADH. The New England Journal of Medicine. 1986;314:1258–1259
  31. Elias LL, Antunes-Rodrigues J, Elias PC, Moreira AC. Effect of plasma osmolality on pituitary-adrenal responses to corticotropin – releasing hormone and atrial natriuretic peptide changes in central diabetes insipidus. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1243–1247
  32. Meller WH, Lewis DA, Gehris TL, et al. Human anterior pituitary response to exogenous arginine vasopressin. Acta Endocrinologica (Copenh). 1991;125:378–384
  33. Balakrishnan SM, Gopalakrishnan V, Mc Neill JR. Endothelin contributes to the hemodynamic effects of vasopressin in spontaneous hypertension. European Journal of Pharmacology. 1997;334:55–60
  34. Katoh K, Yoshida M, Kobayashi Y, et al. Responses induced by arginine-vasopressin injection in the plasma concentrations of adrenocorticotropic hormone, cortisol, growth hormone and metabolites around weaning time in goats. The Journal of Endocrinology. 2005;187:249–256
  35. Szczepansaka-Sadowska E. Interaction of vasopressin and angiotensin II in central control of blood pressure and thirst. Regulatory Peptides. 1996;66:65–71
  36. Fujiwara Y, Hiroyama M, Sanbe A, et al. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. The Journal of Physiology. 2007;584:235–244

PII: S1521-6896(08)00007-4

doi: 10.1016/j.bpa.2008.02.005

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 265-273 , June 2008

Article Tools

* Image Usage & Resolution